Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients

Exclusion Criteria

• •Body weight greater than 45 kg
• •Patients taking anti-seizure medications within 30 days of moxifloxacin dosing
• •Known or suspected allergy to quinolones
• •History of tendon disease/disorder related to quinolone treatment
• •Severe, life-threatening disease with a life expectancy of less than 48 hours and/or known rapidly fatal underlying disease (death expected within 2 months)
• •Abnormal musculoskeletal evaluation at baseline assessment; or chronic musculoskeletal disease (eg, juvenile rheumatoid arthritis); or chronic illness with high risk for chronic or recurrent arthritis or tendinitis (eg, cystic fibrosis, chronic inflammatory bowel disease)
• •Cardiac arrhythmia
• •Evidence of renal or hepatic disease, based on laboratory findings (serum creatinine, total bilirubin, or ALT, \> 1.5 times upper limit of normal) and physical exam
• •Patients receiving Class IA (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic agents
• •Patients taking any medication known to increase the QT interval, eg, amiodarone, astemizole, bepridil, chloroquine, chlorpromazine, cisapride, disopyuramide, dofetilide, droperidol, halofantrine, haloperidol, ibutilide, levomethadyl, mesoradazine, methadone, pimozide, procainamide, quinidine, sotalol, terfenadine
• •Pregnancy
• •Clinically relevant findings in the ECG
• •Participation in another clinical study during the preceding 30 days1 (last treatment from previous study to first treatment of new study)
• •Criteria which in the opinion of the investigator preclude participation for scientific reasons, for reasons of compliance, or for reasons of the patient's safety
• •Patients taking another fluoroquinolone at the time of planned moxifloxacin dosing